DIA Annual Meeting 2025 Blog Post
[event_date_range] – [acf field="event_location"] – Booth [acf field="event_booth"]
RAPS Sponsored: How Drug Developers Can Navigate the Inflation Reduction Act Blog Post
The Inflation Reduction Act (enacted in August 2022) contains profound changes for the healthcare and pharmaceutical industries, shifting responsibility for drug costs away from beneficiaries and onto plans and manufacturers….
Podcast interview with Dr. Elvira Müller. EU joint HTA – decided, but how will it be executed and how should companies prepare Blog Post
In Europe, there are at least as many reimbursement assessment processes in place as European countries. Some of these are transparent and clearly defined like the German AMNOG process, others…
FDA awards new grants to support developing & assessing complex generic drugs Blog Post
Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator is being used to verify and expand biosimulation models for assessing virtual bioequivalence (VBE) of complex generic drugs PRINCETON, N.J.— February 7, 2023. Certara…
Artificial Intelligence: What is it & how can it accelerate rare disease drug development? Blog Post
Large & complex information streams present opportunities for the AI data scientist to aid in diagnosing and detecting signals in treating rare diseases.
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023 Blog Post
PRINCETON, N.J.— February 1, 2023– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of…
Will the Inflation Reduction Act Impact Drug Development Decisions? Blog Post
The short answer is yes. In fact, passage of the Inflation Reduction Act (H.R. 5376) has already impacted at least one company’s drug development plans based on a recent press…
How Drug Developers can Navigate the Inflation Reduction Act of 2022 Blog Post
Learn how the IRA will impact how new drugs are marketed and why negotiating pricing while preparing for lower reimbursements can be challenging for pharmaceutical companies.
